



# Calcitriol, the Bioactive Metabolite of Vitamin D, Increases Ventricular K<sup>+</sup> Currents in Isolated Mouse Cardiomyocytes

María Tamayo<sup>1</sup>, Laura Martin-Nunes<sup>1</sup>, Almudena Val-Blasco<sup>2</sup>, María J. Piedras<sup>1,3</sup>,  
María J. Larriba<sup>4</sup>, Nieves Gómez-Hurtado<sup>1</sup>, María Fernández-Velasco<sup>2\*</sup> and  
Carmen Delgado<sup>1\*</sup>

<sup>1</sup> Biomedical Research Institute “Alberto Sols” CSIC-UAM/CIBER-CV, Madrid, Spain, <sup>2</sup> Innate Immune Response Group, IdiPAZ/CIBER-CV, La Paz University Hospital, Madrid, Spain, <sup>3</sup> University Francisco de Vitoria, Madrid, Spain, <sup>4</sup> Biomedical Research Institute “Alberto Sols” CSIC-UAM/CIBERONC, Madrid, Spain

## OPEN ACCESS

### Edited by:

T. Alexander Quinn,  
Dalhousie University, Canada

### Reviewed by:

Robert Alan Rose,  
University of Calgary, Canada  
Fátima Regina Mena Barreto Silva,  
Universidade Federal de Santa  
Catarina, Brazil

### \*Correspondence:

María Fernández-Velasco  
maria.fernandez@idipaz.es  
Carmen Delgado  
cdelgado@ib.uam.es

### Specialty section:

This article was submitted to  
Cardiac Electrophysiology,  
a section of the journal  
Frontiers in Physiology

Received: 14 May 2018

Accepted: 07 August 2018

Published: xx August 2018

### Citation:

Tamayo M, Martin-Nunes L,  
Val-Blasco A, Piedras MJ, Larriba MJ,  
Gómez-Hurtado N,  
Fernández-Velasco M and Delgado C  
(2018) Calcitriol, the Bioactive  
Metabolite of Vitamin D, Increases  
Ventricular K<sup>+</sup> Currents in Isolated  
Mouse Cardiomyocytes.  
Front. Physiol. 9:1186.  
doi: 10.3389/fphys.2018.01186

Calcitriol, the bioactive metabolite of vitamin D, interacts with the ubiquitously expressed nuclear vitamin D receptor (VDR) to induce genomic effects, but it can also elicit rapid responses via membrane-associated VDR through mechanisms that are poorly understood. The down-regulation of K<sup>+</sup> currents is the main origin of electrophysiological remodeling in pathological hypertrophy and heart failure (HF), which can contribute to action potential prolongation and subsequently increase the risk of triggered arrhythmias. Adult mouse ventricular myocytes were isolated and treated with 10 nM calcitriol or vehicle for 15–30 min. In some experiments, cardiomyocytes were pretreated with the Akt inhibitor triciribine. In the adult mouse ventricle, outward K<sup>+</sup> currents involved in cardiac repolarization are comprised of three components: the fast transient outward current (I<sub>tof</sub>), the ultrarapid delayed rectifier K<sup>+</sup> current (I<sub>kur</sub>), and the non-inactivating steady-state outward current (I<sub>ss</sub>). K<sup>+</sup> currents were investigated using the whole-cell or the perforated patch-clamp technique and normalized to cell capacitance to obtain current densities. Calcitriol treatment of cardiomyocytes induced an increase in the density of I<sub>tof</sub> and I<sub>kur</sub>, which was lost in myocytes isolated from VDR-knockout mice. In addition, calcitriol activated Akt in cardiomyocytes and pretreatment with triciribine prevented the calcitriol-induced increase of outward K<sup>+</sup> currents. In conclusion, we demonstrate that calcitriol via VDR and Akt increases both I<sub>tof</sub> and I<sub>kur</sub> densities in mouse ventricular cardiomyocytes. Our findings may provide new mechanistic clues for the cardioprotective role of this hormone in the heart.

**Keywords:** calcitriol, potassium currents, cardiomyocytes, vitamin D, cellular electrophysiology, ionic channel remodeling, Akt

## INTRODUCTION

Cardiac remodeling is the response of the heart to various damaging stimuli, such as long standing hypertension or myocardial infarction. This physiological process is characterized by the triggering of “compensatory” pathways such as, the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS). Initially, this mechanism is beneficial but sustained activation

of neurohormonal systems can cause additional damage to the heart, commonly in the form of hypertrophy, apoptosis and fibrosis, contributing to the adverse remodeling process, and accelerating the transition toward heart failure (HF) (Heusch et al., 2014; Hartupee and Mann, 2017). Moreover, ventricular remodeling modifies the functioning of ion channels and transporters such as that cardiac rhythm disturbances occur, which is termed “arrhythmogenic remodeling” (Nattel et al., 2007). K<sup>+</sup> currents play key roles in shaping the action potentials (APs), and adverse ventricular remodeling induces down-regulation of several K<sup>+</sup> currents, which are associated with prolonged QT intervals, increased risk of malignant arrhythmias and sudden cardiac death. It is well known that almost one-half of HF patients die from sudden cardiac death, most probably due to ventricular arrhythmias (Nass et al., 2008; Lehnart et al., 2009).

Vitamin D deficiency is highly prevalent worldwide, an in particular among the elderly population (Holick, 2007). Low levels of vitamin D have been associated with worse outcomes in patients with HF (Liu et al., 2011; Gotsman et al., 2012) and vitamin D supplementation has been shown to ameliorate symptoms and decrease mortality (Gotsman et al., 2012; Witte et al., 2016). The biologically active form of vitamin D is 1,25-dihydroxycholecalciferol or calcitriol, which translocates the cell membrane and cytoplasm to reached the nucleus of the cell, where it binds to vitamin D receptor (VDR). In turn, VDR can bind to retinoic X receptor to serve as a nuclear transcription factors, regulating the expression of numerous genes. In addition to these genomic responses, calcitriol can mediate rapid responses by binding to cell membrane VDR, interacting with ion channels (Menegaz et al., 2011; Zanatta et al., 2012; Tamayo et al., 2017) and membrane-based signaling pathways (Larriba et al., 2014).

Previous reports have postulated that activation of the PI3K pathway can modulate cardiac K<sup>+</sup> channels in cardiomyocytes (Yang et al., 2012; Gomez-Hurtado et al., 2014) and Akt is a well-known target of PI3K, activated by calcitriol in other cellular systems.

Calcitriol has been demonstrated to initiate a VDR-dependent rapid activation of PI3K/Akt signaling in osteoblasts (Vertino et al., 2005). In addition, the anti-apoptotic properties of calcitriol in osteoblasts are thought to be related to the non-genomic activation of a VDR/PI3K/Akt pathway (Zhang and Zanello, 2008). Moreover, activation of Akt by calcitriol has been observed in leukemia, squamous cell carcinoma and skeletal muscle cells (Ma et al., 2006; Zhang et al., 2006; Buitrago et al., 2012).

Vitamin D receptor has been identified in numerous cardiovascular cell types including cardiomyocytes (Tishkoff et al., 2008; Norman and Powell, 2014). Whereas experimental studies have demonstrated rapid effects of calcitriol on cardiac calcium channels (Zanatta et al., 2012; Tamayo et al., 2017), its effects on cardiac potassium channels remain elusive. Thus, in the present study we used patch-clamp recordings to examine the rapid responses of calcitriol on the main K<sup>+</sup> currents responsible for cardiac repolarization in the mouse and the potential mechanism (s) involved. Our results show that calcitriol increases outward K<sup>+</sup> current densities in ventricular myocytes

via Akt signaling, and that this mechanism can contribute to the protective effect of vitamin D on the heart.

## MATERIALS AND METHODS

### Animals

Adult (2–3 months old) male C57BL/6J mice and VDR knockout (KO) mice were originally generated by Dr. Marie Demay (Harvard Medical School, Boston, MA, United States) (Li et al., 1997) and kindly donated by Dr Alberto Muñoz (Biomedical Research Institute “Alberto Sols” CSIC-UAM, Madrid, Spain) were used. All experiments on mice were performed after approval by the Bioethical Committee of the *Consejo Superior de Investigaciones Científicas* following recommendations of the Spanish Animal Care and Use Committee (Proex 035-15) according to the guidelines for ethical care of experimental animals of the European Union (2010/63/EU).

### Electrophysiological Procedures and Data Analysis

Adult mouse ventricular cardiomyocytes were isolated as described (Delgado et al., 2015). Single rod-shaped, Ca<sup>2+</sup>-tolerant myocytes were treated with calcitriol or vehicle for 15–30 min and used for electrophysiological recordings within 4 h of isolation.

The electrophysiological protocols used to record APs and K<sup>+</sup> currents in this study were the same as those previously described (Trépanier-Boulay et al., 2001; Brouillette et al., 2004; Gómez-Hurtado et al., 2017). Briefly, ventricular myocytes were placed in a chamber mounted on the stage of an inverted microscope and allowed to adhere for 5 min before being superfused with Tyrode’s solution. Whole-cell voltage-clamp and current clamp recordings were obtained in the ruptured patch configuration using an Axopatch 200B patch clamp amplifier (Molecular Devices, Sunnyvale, CA, United States). The patch pipette resistance was 1.0–2 MΩ and the pipette was filled with a solution containing (in mM): 135 KCl, 4 MgCl<sub>2</sub>, 5 EGTA, 10 HEPES, 10 glucose, 5 Na<sub>2</sub>ATP, and 5 disodium creatine phosphate; the pH was adjusted to 7.2 with KOH. Whole-cell voltage clamp experiments were performed at room temperature (24–26°C), whereas whole-cell current clamp experiments (AP recordings) were carried out at 36–37°C.

The external solution for K<sup>+</sup> current recordings contained (in mM): 135 NaCl, 10 glucose, 10 HEPES, 1 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 5.4 KCl, and 2 CoCl<sub>2</sub>; the pH was adjusted to 7.4 with NaOH. The external solution for AP recordings contained (in mM): 140 NaCl, 10 glucose, 10 HEPES, 1.1 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, and 4 KCl; the pH was adjusted to 7.2 with KOH.

Current density was calculated from the current amplitude normalized to the membrane capacitance. Membrane capacitance (C<sub>m</sub>) was elicited by applying ±10 mV voltage steps from –60 mV and C<sub>m</sub> was calculated according to the following equation:

$$C_m = \tau_c I_0 / \Delta V_m [1 - (I_\infty / I_0)]$$

where  $\tau_c$  is the time constant of the membrane capacitance,  $I_0$  the maximum capacitance current value,  $\Delta V_m$  the amplitude of the voltage step, and  $I_\infty$  the amplitude of the steady-state current.

In some experiments the perforated patch-clamp technique was used to record the time course of the effects of calcitriol on total K<sup>+</sup> currents. Perforated-patch recordings were started 5–25 min after a giga-seal was obtained. Just before use, the tip of the pipette was filled with antibiotic-free intracellular solution and the remainder of the pipette was backfilled with pipette solution containing 250  $\mu\text{g}/\text{mL}$  amphotericin B. Depolarizing pulses from a holding potential of  $-60$  to  $-40$  mV were used to monitor the access resistance. Recordings of  $I_{total}$  were initiated when the access resistance was stabilized at 6–13 M $\Omega$ .  $I_{total}$  was elicited by depolarizing pulses to  $+50$  mV from a holding potential of  $-80$  mV every 10 s. The extracellular solution for  $I_{total}$  recordings for perforated-patch experiments was the same that we used for the whole-cell experiments. The intracellular solution used to elicit recordings in the perforated-patch configuration contained (in mM): 110 potassium aspartate, 20 KCl, 1 EGTA, 1 CaCl<sub>2</sub>, 5 HEPES, 1 MgCl<sub>2</sub>, 250  $\mu\text{g}/\text{mL}$  amphotericin B; pH adjusted to 7.2 with KOH.

## Western Blotting

Cardiomyocytes were homogenized in a buffer containing 320 mM sucrose, 50 mM Tris and 0.2% nonidet P-40, supplemented with a phosphatase, trypsin and protease inhibitor cocktail (Sigma-Aldrich, Madrid, Spain). Lysed cells were centrifuged at 13,000 rpm for 10 min at 4°C and the supernatants were used for immunoblotting. Equal amounts of protein were separated on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% non-fat milk and incubated overnight with the following primary antibodies: phospho-Akt (Thr308) and Akt (Cell Signaling Technology, Danvers, MA, United States). Blots were incubated with peroxidase-conjugated secondary antibodies and immunoreactive bands were detected using the Amersham ECL<sup>TM</sup> protein detection system (GE Healthcare, Piscataway, NJ, United States) and medical x-ray film blue (Agfa HealthCare, Morstel, Belgium). Films were scanned with a NIKON camera and quantified by ImageJ software (NIH, Bethesda, MD, United States).

## Reagents

The Akt inhibitor triciribine, calcitriol and amphotericin B were purchased from Sigma-Aldrich Co. (St. Louis, MO, United States). A stock solution of calcitriol was prepared using DMSO as vehicle (<0.01% DMSO).

## Statistical Analysis

Data are presented as means  $\pm$  SEM. Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, United States). Statistical significance was evaluated using unpaired or paired Student's *t*-test when appropriate. A value of  $P < 0.05$  was considered statistically significant.

## RESULTS

### Calcitriol Increases Outward K<sup>+</sup> Currents

For the experimental setup, the main K<sup>+</sup> currents responsible for the AP repolarization phase in the mouse were recorded in ventricular myocytes treated either with vehicle or 10 nM calcitriol for 15–30 min. In the adult mouse ventricle, outward K<sup>+</sup> currents involved in cardiac repolarization comprise three components that can be distinguished by their specific time and voltage dependency and also their sensitivity to pharmacological agents. **Figure 1** illustrates the protocol used to identify the three components: the fast transient outward current ( $I_{tof}$ ), the ultrarapid delayed rectifier K<sup>+</sup> current ( $I_{kur}$ ) and the non-inactivating steady-state outward current ( $I_{ss}$ ). As a first step the total K<sup>+</sup> currents were recorded by applying 300 ms depolarizing steps from  $-50$  to  $+50$  mV from a holding potential of  $-80$  mV (**Figure 1A**). Then,  $I_{tof}$  was inactivated by applying a short prepulse (100 ms step at  $-30$  mV) from a holding potential of  $-80$  mV, followed by depolarizing steps from  $-50$  to  $+50$  mV.  $I_{tof}$  was then calculated by subtracting the current recording with (**Figure 1A**) and without (**Figure 1B**) the inactivating prepulse. The current that remains after  $I_{tof}$  was inactivated, is composed of  $I_{ss}$  and  $I_{kur}$ . To separate both currents, a low concentration of 4-aminopyridine (4-AP, 250  $\mu\text{M}$ ), which selectively blocks  $I_{kur}$ , was applied to cells that were prepulsed to inactivate  $I_{tof}$ . The current remaining after this protocol is  $I_{ss}$  (**Figure 1C**), and  $I_{kur}$  can then be obtained by subtracting the current in the absence (**Figure 1B**) and in the presence (**Figure 1C**) of 4-AP. **Figure 2A** shows representative recordings of total K<sup>+</sup> currents obtained in 1 myocyte treated with vehicle and in 1 myocyte treated with 10 nM calcitriol. **Figure 2B** shows mean current-voltage (IV) curves for  $I_{total}$  density. Myocytes treated with calcitriol showed higher values of  $I_{total}$  density than those treated with vehicle (at  $+50$  mV, vehicle  $38.2 \pm 2.2$  pA/pF,  $n = 27$ ; calcitriol  $50.5 \pm 3.1$  pA/pF,  $n = 30$ ;  $P < 0.01$ ). In another group of experiments we tested the effect of calcitriol on total K<sup>+</sup> currents by analyzing the time dependence of the effect in continuous recordings. For that, we used the perforated patch-clamp technique which preserves the cell from loss of some cytosolic second messengers due to intracellular dialysis that occurs during prolonged whole-cell recordings. **Figure 2C** (upper panel) shows representative traces of  $I_{total}$  corresponding to points a, b, and c on the graph below (lower panel). Peak  $I_{total}$  was elicited by depolarizing pulses from a holding potential of  $-80$  to  $+50$  mV every 10 s over 19 min. Application of calcitriol induced a rapid increase in  $I_{total}$ , which reached a maximum effect at 9–10 min; then, the cardiomyocyte was perfused with calcitriol-free solution, which led to a progressive decrease in  $I_{total}$  toward control values after  $\sim 10$  min of washout. Similar results were obtained in three other cardiomyocytes.

**Figure 3A** (left panel) shows representative recordings of  $I_{tof}$  obtained in 1 myocyte treated with vehicle and in 1 myocyte treated with 10 nM calcitriol a, and **Figure 3A** (right panel) shows (IV) curves for  $I_{tof}$  density. Myocytes treated with calcitriol showed higher values of  $I_{tof}$  density than those treated with vehicle (at  $+50$  mV, vehicle:  $10.6 \pm 0.9$  pA/pF,  $n = 23$ ; calcitriol:  $15.9 \pm 1.4$  pA/pF,  $n = 28$ ;  $P < 0.01$ ). **Figure 3B**

(left panel) illustrates representative recordings of  $I_{kur}$  obtained in 1 myocyte treated with vehicle and in 1 myocyte treated with 10 nM calcitriol, **Figure 3B** (right panel) shows mean IV curves for  $I_{kur}$  density). Myocytes treated with calcitriol showed higher values of  $I_{kur}$  density than those treated with vehicle (at +50 mV, vehicle:  $13.2 \pm 1.2$  pA/pF,  $n = 25$ ; calcitriol:  $19.4 \pm 1.8$  pA/pF,  $n = 24$ ;  $P < 0.01$ ). Representative recordings of  $I_{ss}$  obtained in 1 myocyte treated with vehicle and in 1 myocyte treated with 10 nM calcitriol are shown in **Figure 3C** left panel, and mean IV curves for  $I_{ss}$  density are shown in **Figure 3C** right panel.  $I_{ss}$  values in myocytes treated with vehicle (at +50 mV,  $12.4 \pm 0.8$  pA/pF,  $n = 12$ ) were similar to those of myocytes treated with calcitriol (at +50 mV,  $12.8 \pm 0.5$  pA/pF,  $n = 26$ ).


### Calcitriol Treatment Does Not Modify Action Potentials Duration

Since an increase in outward current can modulate repolarization, we carried out current clamp experiments to measure AP duration (APD) in myocytes treated with vehicle or calcitriol. Representative traces of APs recorded in 1 ventricular myocyte treated with vehicle (left) and in 1 myocyte treated with calcitriol (right) are shown in **Figure 4A**. Mean values of APD measured at 20, 50, and 90% of repolarization obtained in ventricular myocytes treated with vehicle or calcitriol are illustrated in **Figure 4B**. Values of APD were similar in both groups: APD20, vehicle  $1.2 \pm 0.6$  ms vs. calcitriol  $1.3 \pm 0.1$  ms;

APD50, vehicle  $3.4 \pm 0.3$  ms vs. calcitriol  $2.9 \pm 0.2$  ms; APD90, vehicle  $25.2 \pm 3.5$  ms vs. calcitriol  $23.5 \pm 2.5$  ms ( $n = 10$  cells treated with vehicle or calcitriol). In addition, no differences were observed in resting potential (RP) or AP amplitude in myocytes treated with vehicle or with calcitriol ( $-78.3 \pm 1.9$  mV vs.  $-77.4 \pm 1.4$  mV for RP and  $117.7 \pm 3.7$  mV vs.  $120.7 \pm 3.6$  mV for AP amplitude, vehicle vs. calcitriol-treated cells, respectively).


### Vitamin D Receptor Is Involved in the Effect of Calcitriol on Outward K<sup>+</sup> Currents

To examine the participation of VDR in the effect of calcitriol on  $I_{tof}$  and  $I_{kur}$ , ventricular myocytes were isolated from VDR-KO mice and treated with vehicle or 10 nM calcitriol for 15–30 min. Representative recordings of  $I_{tof}$ , obtained in 1 VDR-KO myocyte treated with vehicle or 10 nM calcitriol are shown in **Figure 5A** left panel, and mean IV curves for  $I_{tof}$  density are shown in **Figure 5A** right panel. In VDR-deficient myocytes, calcitriol was unable to increase  $I_{tof}$  density when compared with vehicle (at +50 mV, vehicle:  $13.1 \pm 1.8$  pA/pF,  $n = 10$ ; calcitriol:  $12.5 \pm 2.2$  pA/pF,  $n = 6$ ). Representative recordings of  $I_{kur}$ , obtained in 1 VDR-KO myocyte treated with vehicle and in 1 VDR-KO myocyte treated with 10 nM calcitriol are shown in **Figure 5B** (left panel), and mean IV curves for  $I_{kur}$  density are shown in **Figure 5B** right panel. In the absence of VDR, the mean  $I_{kur}$  density was similar between myocytes treated



**FIGURE 1 |** Protocol used to isolate the fast transient outward K<sup>+</sup> current ( $I_{tof}$ ), the ultrarapid delayed rectifier K<sup>+</sup> current ( $I_{kur}$ ) and the non-inactivating steady-state outward current ( $I_{ss}$ ) in mouse ventricular cardiomyocytes. **(A)** Superimposed current records of total K<sup>+</sup> currents activated by voltage protocol shown on the left. **(B)** Family of K<sup>+</sup> currents obtained from the same cell as in **(A)** ( $C_m = 212$  pF), but voltage-clamp steps were each preceded by an inactivating pulse at  $-30$  mV, shown in the left panel.  $I_{tof}$  was then calculated by subtracting the current recording with **(A)** and without **(B)** the inactivating prepulse. **(C)** Superimposed current records of K<sup>+</sup> currents obtained after the same cell as those in **(B)** ( $C_m = 212$  pF) was exposed with 4-AP, which selectively blocks  $I_{kur}$ . The current remaining after this protocol is  $I_{ss}$ , and  $I_{kur}$  was then obtained by subtracting the current in the absence of 4-AP from the current in the presence of 4-AP.

Q4  
Q5




**FIGURE 2 |** Calcitriol increases total K<sup>+</sup> currents in ventricular myocytes. **(A)** Superimposed current records of total K<sup>+</sup> current ( $I_{total}$ ) for 1 myocyte treated with vehicle and 1 myocyte treated with 10 nM calcitriol. **(B)** Current-voltage curves for  $I_{total}$  density obtained in myocytes treated with vehicle or calcitriol. **(C)** Time course of the effect of calcitriol on  $I_{total}$  by perforated patch-clamp recordings. The black points in the figure are peak outward currents recorded at +50 mV every 10 s. Horizontal line indicates exposure to calcitriol 10 nM and washout. Upper panel shows  $I_{total}$  traces at +50 mV corresponding to time 0 min **(a)**, 9 min after calcitriol perfusion **(b)**, and ~10 min after washout **(c)**. Data are expressed as means ± SEM.  $C_m$  = membrane capacitance in pF. \*\*\* $P < 0.001$ ; \*\* $P < 0.01$ ; \* $P < 0.05$ .

with vehicle or calcitriol (at +50 mV, vehicle:  $9.9 \pm 1.0$  pA/pF,  $n = 6$ ; calcitriol:  $11.2 \pm 1.4$  pA/pF,  $n = 9$ ). Representative recordings of  $I_{ss}$ , obtained in 1 VDR-KO myocyte treated with

vehicle and in 1 VDR-KO myocyte treated with 10 nM calcitriol are shown in **Figure 5C** (left panel), and mean IV curves for  $I_{ss}$  density in VDR-KO myocytes treated with vehicle or calcitriol are

571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627


628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684



**FIGURE 3 |** The fast transient outward K<sup>+</sup> current (I<sub>tof</sub>) and the ultrarapid delayed rectifier K<sup>+</sup> current (I<sub>kur</sub>) are significantly increased in calcitriol-treated myocytes. **(A) Left panel:** representative I<sub>tof</sub> traces for 1 myocyte treated with vehicle and 1 myocyte treated with 10 nM calcitriol. **Right panel:** I/V curves for I<sub>tof</sub> density obtained in myocytes treated with vehicle or with 10 nM calcitriol. **(B) Left panel:** representative I<sub>kur</sub> traces for 1 myocyte treated with vehicle and 1 myocyte treated with calcitriol. **Right panel:** I/V curves for I<sub>kur</sub> density obtained in myocytes treated with vehicle or calcitriol. **(C) Left panel:** representative I<sub>ss</sub> traces for 1 myocyte treated with vehicle and 1 myocyte treated with calcitriol. **Right panel:** I/V curves for I<sub>ss</sub> density obtained in myocytes treated with vehicle or calcitriol. Data are expressed as means ± SEM. C<sub>m</sub> = membrane capacitance in pF. \*\*\*P < 0.001; \*\*P < 0.01; \*P < 0.05.

685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741

742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798



**FIGURE 4 |** Effects of calcitriol on Action Potentials Duration **(A)** Representative traces of action potentials recorded in 1 myocyte treated with vehicle and in 1 myocyte treated with 10 nM calcitriol. **(B)** Bar graph showing mean action potential duration (APD) values measured at 20, 50, and 90% of repolarization (APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub>, respectively). Data are expressed as means ± SEM.

shown in **Figure 5C** right panel. Results showed that calcitriol had no effect on  $I_{ss}$  density in VDR-KO myocytes (at +50 mV, vehicle:  $8.7 \pm 0.6$  pA/pF,  $n = 13$ ; calcitriol:  $8.8 \pm 0.6$  pA/pF,  $n = 10$ ).


### Akt Mediates the Stimulatory Effect of Calcitriol on $I_{tof}$ and $I_{kur}$

It has been postulated that the activation of the PI3K pathway can modulate cardiac K<sup>+</sup> channels (Yang et al., 2012; Gomez-Hurtado et al., 2014). To explore the implication of PI3K signaling in the calcitriol-induced increase of  $I_{tof}$  and  $I_{kur}$  densities, we questioned whether calcitriol activates Akt, a known target of PI3K, in ventricular myocytes (Shioi et al., 2002; McMullen et al., 2003). We observed a significant activation of Akt (measured as phosphorylation) after 15 min of calcitriol

treatment (**Figures 6A,B**). We therefore measured  $I_{tof}$ ,  $I_{kur}$ , and  $I_{ss}$  in myocytes pretreated with 1  $\mu$ M of the Akt inhibitor triciribine. Representative traces obtained in myocytes pretreated with triciribine and then treated with vehicle or calcitriol are shown in **Figures 7A–C**, respectively (left panels), and mean IV curves for  $I_{tof}$ ,  $I_{kur}$  and  $I_{ss}$  densities in both situations are shown in the corresponding right panels. The results showed that treatment with triciribine prevented the stimulatory effect of calcitriol on  $I_{tof}$  and  $I_{kur}$ .

## DISCUSSION

Cardiac APs are the consequence of the coordinated functioning of inward and outward current flowing through specialized




**FIGURE 5 |** Effect of calcitriol on I<sub>tof</sub> and I<sub>kur</sub> involves binding to the vitamin D receptor. **(A)** Left panel: representative traces of I<sub>tof</sub> obtained in 1 VDR-KO myocyte treated with vehicle and in 1 VDR-KO myocyte treated with 10 nM calcitriol. Right panel: I/V curves for I<sub>tof</sub> density obtained in VDR-KO myocytes treated with vehicle or calcitriol. **(B)** Left panel: representative traces of I<sub>kur</sub> obtained in 1 VDR-KO myocyte treated with vehicle and in 1 VDR-KO myocyte treated with 10 nM calcitriol. Right panel: I/V curves for I<sub>kur</sub> density obtained in VDR-KO myocytes treated with vehicle or calcitriol. **(C)** Left panel: representative traces of I<sub>ss</sub> obtained in 1 VDR-KO myocyte treated with vehicle and in 1 VDR-KO myocyte treated with 10 nM calcitriol. Right panel: I/V curves for I<sub>ss</sub> density obtained in VDR-KO myocytes treated with vehicle or calcitriol. Data are expressed as means ± SEM. C<sub>m</sub> = membrane capacitance in pF.

proteins (ionic channels) that open and close in a voltage- and time-dependent manner allowing rhythmic and effective cardiac contractions (Gaborit et al., 2007). It is well known that K<sup>+</sup>

current density is reduced during heart remodeling under various pathological conditions including left ventricular hypertrophy and HF. This process is associated with prolonged QT interval,






increased risk of malignant arrhythmias and sudden cardiac death (Ravens and Cerbai, 2008). Here, we tested the hypothesis that calcitriol might have a cardioprotective effect by increasing K<sup>+</sup> currents, thereby circumventing inappropriate prolongation of the APD during pathology. In mice, the repolarization phase of the AP is determined principally by the outward currents I<sub>tof</sub> and I<sub>kur</sub>, which account for the remarkably abbreviated APs and the absence of a clear plateau phase in this species. We found that calcitriol significantly increased I<sub>tof</sub> and I<sub>kur</sub> densities. In apparent contrast, we found that the APD was similar in myocytes treated or not with calcitriol. The lack of the effect of increased K<sup>+</sup> currents on the APD in calcitriol-treated myocytes indicates that calcitriol might affect other ionic currents that influence the APD. In this sense, we previously demonstrated that calcitriol can increase L-type calcium current (I<sub>CaL</sub>) density in ventricular myocytes (Tamayo et al., 2017). The increase of I<sub>CaL</sub> might counterbalance the effect of increased outward K<sup>+</sup> currents in calcitriol-treated myocytes, preserving the APD. Calcitriol can induce genomic (transcription-dependent) and non-genomic (transcription-independent) actions. Indeed, there

is a general agreement in the idea that calcitriol effects observed within minutes (such as those described in the present study) involve only non-genomic effects mediated by extra-nuclear mechanisms (Mizwicki and Norman, 2009). Most calcitriol actions are mediated by VDR. Classic nuclear VDR is required for genomic effects, whereas non-genomic actions are thought to be mediated by a fraction of VDR located in the cytosol or at the plasma membrane (Norman et al., 2001a,b). In this regards, *in silico* studies have been useful to determine exactly how calcitriol binds to VDR to regulate both genomic and non-genomic responses. An alternative ligand-binding pocket has been identified in VDR that specifically mediates non-genomic actions and that partially overlaps the genomic pocket described in the experimentally determined x-ray structure (Mizwicki et al., 2004). In the present study, we used VDR-KO mice to determine whether the effect of calcitriol on K<sup>+</sup> currents in cardiomyocytes involves VDR. Our results clearly show that the absence of VDR abolished all changes in K<sup>+</sup> currents induced by the acute administration of calcitriol, demonstrating that these effects are VDR-dependent. Consistent with this, we have previously described that calcitriol exerts VDR-dependent non-genomic effects on Ca<sup>2+</sup> current and PKA signaling in cardiomyocytes (Tamayo et al., 2017), which is in line with the findings by Zanello and Norman (2006) showing that a functional VDR is required for the rapid increase in Cl<sup>-</sup> current and for the shift in the peak activation of I<sub>CaL</sub> current induced by calcitriol in osteoblasts. As VDR-KO mice do not express VDR, this model does not allow us to discriminate precisely which VDR location mediates these observed effects. We are, however, inclined to favor a non-genomic action mediated by membrane VDR due to the short time required (15–30 min) and the fact that VDR has been reported to be expressed in the tubular system of ventricular myocytes (Tishkoff et al., 2008), a region where voltage-gated calcium and potassium channels are predominantly localized (Takeuchi et al., 2000; Brette and Orchard, 2003). On the other hand, protein disulfide isomerase family A member 3 (PDIA3) has been proposed as a membrane receptor for calcitriol that mediates some of its non-genomic effects in chondrocytes, osteoblasts and other cell types (Boyan et al., 2003; Doroudi et al., 2014a,b). Intriguingly, both PDIA3 and VDR are located in caveolae in many tissues and cell types, and an interaction between them has been observed, suggesting that VDR and PDIA3 might both be required for some non-genomic actions of calcitriol (Sequeira et al., 2012; Chen et al., 2013). As the effects of calcitriol on K<sup>+</sup> current in cardiomyocytes are completely abolished in VDR-KO cells we would argue that PDIA3 is not implicated in the described effect, although clearly experiments with PDIA3-KO cells would be necessary to completely discard the possibility that both VDR and PDIA3 are involved.

Several reports have shown that calcitriol binding to plasma membrane VDR induces rapid non-transcriptional responses through the activation of different signaling pathways including PI3K/Akt (Buitrago et al., 2012; Salles et al., 2013). This pathway is widely expressed in eukaryotes and is known to play key roles in growth, differentiation, proliferation, and survival (Cantley, 2002). In the heart,



**FIGURE 7 |** Inhibition of Akt signaling prevents the increase in  $I_{tof}$  and  $I_{kur}$  densities induced by calcitriol. **(A)** *Left panel:*  $I_{tof}$  traces obtained in 1 myocyte treated with 1  $\mu$ M triciribine and in 1 myocyte treated with 1  $\mu$ M triciribine plus 10 nM calcitriol. *Right panel:* I/V curves for  $I_{tof}$  density obtained in myocytes treated with 1  $\mu$ M triciribine or with triciribine plus 10 nM calcitriol. **(B)** *Left panel:*  $I_{kur}$  traces obtained in one myocyte treated with 1  $\mu$ M triciribine and in 1 myocyte treated with 1  $\mu$ M triciribine plus 10 nM calcitriol. *Right panel:* I/V curves for  $I_{kur}$  density obtained in myocytes treated with 1  $\mu$ M triciribine or with triciribine plus 10 nM calcitriol. **(C)** *Left panel:*  $I_{ss}$  traces obtained in 1 myocyte treated with 1  $\mu$ M triciribine and in 1 myocyte treated with 1  $\mu$ M triciribine plus 10 nM calcitriol. *Right panel:* I/V curves for  $I_{ss}$  density obtained in myocytes treated with 1  $\mu$ M triciribine or with triciribine plus 10 nM calcitriol. Data are expressed as means  $\pm$  SEM.  $C_m$ , membrane capacitance; TCB, triciribine.

PI3K/Akt activation has been related to both physiological cardiac enlargement and protection (McMullen et al., 2003; Weeks et al., 2012). Moreover, it is believed that the

PI3K/Akt pathway might regulate cardiac ion channels and arrhythmogenesis (Ballou et al., 2015). Our results show that calcitriol activates Akt in adult ventricular myocytes, and

1141 its pharmacological inhibition prevents the calcitriol-induced  
1142 increase of I<sub>tof</sub> and I<sub>Kur</sub> densities.

1143 In sum, we demonstrate that calcitriol binding to VDR  
1144 increases the density of the two main K<sup>+</sup> currents responsible  
1145 for the rapid repolarization of the AP in the mouse, I<sub>tof</sub> and I<sub>Kur</sub>.  
1146 Our study also supports a role of Akt signaling in this stimulatory  
1147 effect.

1148  
1149  
1150 **AUTHOR CONTRIBUTIONS**

1151 MT performed most of the experiments and analyzed the data.  
1152 LM-N isolated ventricular myocytes and performed most of  
1153 the western blotting experiments. MP took part in the critical  
1154 discussion and editing of the manuscript. ML provided VDR-  
1155 KO mice. AV-B and NG-H helped with western blotting.  
1156 ML and NG-H took part in the critical discussion and  
1157 editing of the manuscript. MF-V designed the experiments,  
1158 reviewed the data, and wrote the manuscript. CD performed  
1159 some electrophysiological experiments, conceived the hypothesis,  
1160

1161  
1162 **REFERENCES**

1163  
1164 Ballou, L. M., Lin, R. Z., and Cohen, I. S. (2015). Control of cardiac repolarization  
1165 by phosphoinositide 3-kinase signaling to ion channels. *Circ. Res.* 116, 127–137.  
1166 doi: 10.1161/CIRCRESAHA.116.303975  
1167 Boyan, B. D., Sylvia, V. L., McKinney, N., and Schwartz, Z. (2003). Membrane  
1168 actions of vitamin D metabolites 1α,25(OH)<sub>2</sub>D<sub>3</sub> and 24R,25(OH)<sub>2</sub>D<sub>3</sub> are  
1169 retained in growth plate cartilage cells from vitamin D receptor knockout mice.  
1170 *J. Cell. Biochem.* 90, 1207–1223. doi: 10.1002/jcb.10716  
1171 Brette, F., and Orchard, C. (2003). T-tubule function in mammalian cardiac  
1172 myocytes. *Circ. Res.* 92, 1182–1192. doi: 10.1161/01.RES.0000074908.17214.FD  
1173 Brouillette, J., Clark, R. B., Giles, W. R., and Fiset, C. (2004). Functional properties  
1174 of K<sup>+</sup> currents in adult mouse ventricular myocytes. *J. Physiol.* 559, 777–798.  
1175 doi: 10.1113/jphysiol.2004.063446  
1176 Buitrago, C. G., Arango, N. S., and Boland, R. L. (2012). 1α,25(OH)<sub>2</sub>D<sub>3</sub>-dependent  
1177 modulation of Akt in proliferating and differentiating C2C12 skeletal muscle  
1178 cells. *J. Cell. Biochem.* 113, 1170–1181. doi: 10.1002/jcb.23444  
1179 Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. *Science* 296,  
1180 1655–1657. doi: 10.1126/science.296.5573.1655  
1181 Chen, J., Doroudi, M., Cheung, J., Grozier, A. L., Schwartz, Z., and Boyan, B. D.  
1182 (2013). Plasma membrane Pdia3 and VDR interact to elicit rapid responses  
1183 to 1α,25(OH)<sub>2</sub>D<sub>3</sub>. *Cell. Signal.* 25, 2362–2373. doi: 10.1016/j.celsig.2013.  
1184 07.020  
1185 Delgado, C., Ruiz-Hurtado, G., Gomez-Hurtado, N., Gonzalez-Ramos, S.,  
1186 Rueda, A., Benito, G., et al. (2015). NOD1, a new player in cardiac function  
1187 and calcium handling. *Cardiovasc. Res.* 106, 375–386. doi: 10.1093/cvr/cvv118  
1188 Doroudi, M., Boyan, B. D., and Schwartz, Z. (2014a). Rapid 1α,25(OH)<sub>2</sub>D<sub>3</sub>  
1189 membrane-mediated activation of Ca<sup>2+</sup>/calmodulin-dependent protein kinase  
1190 II in growth plate chondrocytes requires Pdia3. PLAA and caveolae. *Connect.*  
1191 *Tissue Res.* 55(Suppl. 1), 125–128.  
1192 Doroudi, M., Chen, J., Boyan, B. D., and Schwartz, Z. (2014b). New insights  
1193 on membrane mediated effects of 1α,25-dihydroxy vitamin D<sub>3</sub> signaling in  
1194 the musculoskeletal system. *Steroids* 81, 81–87. doi: 10.1016/j.steroids.2013.  
1195 10.019  
1196 Gaborit, N., Le Bouter, S., Szuts, V., Varro, A., Escande, D., Nattel, S., et al. (2007).  
1197 Regional and tissue specific transcript signatures of ion channel genes in the  
1198 non-diseased human heart. *J. Physiol.* 582, 675–693. doi: 10.1113/jphysiol.2006.  
1199 126714  
1200 Gómez-Hurtado, N., Domínguez-Rodríguez, A., Mateo, P., Fernández-  
1201 Velasco, M., Val-Blasco, A., Aizpún, R., et al. (2017). Beneficial effects of  
1202 leptin treatment in a setting of cardiac dysfunction induced by transverse aortic  
1203 constriction in mouse. *J. Physiol.* 595, 4227–4243. doi: 10.1113/JP274030

1198 supervised the project, reviewed the data, and wrote the  
1199 manuscript.

1200  
1201  
1202 **FUNDING**

1203 This work was supported by grants SAF2014-57190R,  
1204 SAF2017-84777R, and SAF2016-76377R from the Spanish  
1205 Ministerio de Industria, Economía y Competitividad and  
1206 PI14/01078 and PI17/01344 from ISCIII, Fondos FEDER  
1207 and CIBER-CV and CIBERONC, networks funded by  
1208 ISCIII.

1209  
1210  
1211 **ACKNOWLEDGMENTS**

1212 We thank Drs. M.B. Demay and A. Muñoz for providing VDR-  
1213 KO mice. We are grateful to María Gracia González-Bueno for  
1214 her technical assistance and Dr. Kenneth McCreath for English  
1215 editing.

1216  
1217  
1218  
1219  
1220 Gomez-Hurtado, N., Fernandez-Velasco, M., Fernandez-Alfonso, M., Bosca, L.,  
1221 and Delgado, C. (2014). Prolonged leptin treatment increases transient outward  
1222 K<sup>+</sup> current via upregulation of Kv4.2 and Kv4.3 channel subunits in adult rat  
1223 ventricular myocytes. *Pflugers Arch.* 466, 903–914. doi: 10.1007/s00424-013-  
1224 1348-3  
1225 Gotsman, I., Shauer, A., Zwas, D. R., Hellman, Y., Keren, A., Lotan, C., et al. (2012).  
1226 Vitamin D deficiency is a predictor of reduced survival in patients with heart  
1227 failure; vitamin D supplementation improves outcome. *Eur. J. Heart Fail.* 14,  
1228 357–366. doi: 10.1093/eurjhf/hfr175  
1229 Hartupej, J., and Mann, D. L. (2017). Neurohormonal activation in heart failure  
1230 with reduced ejection fraction. *Nat. Rev. Cardiol.* 14, 30–38. doi: 10.1038/  
1231 nrcardio.2016.163  
1232 Heusch, G., Libby, P., Gersh, B., Yellon, D., Böhm, M., Lopaschuk, G., et al. (2014).  
1233 Cardiovascular remodelling in coronary artery disease and heart failure. *Lancet*  
1234 383, 1933–1943. doi: 10.1016/S0140-6736(14)60107-0  
1235 Holick, M. F. (2007). Vitamin D deficiency. *N. Engl. J. Med.* 357, 266–281.  
1236 doi: 10.1056/NEJMr070553  
1237 Larriba, M. J., González-Sancho, J. M., Bonilla, F., and Muñoz, A. (2014).  
1238 Interaction of vitamin D with membrane-based signaling pathways. *Front.*  
1239 *Physiol.* 5:60. doi: 10.3389/fphys.2014.00060  
1240 Lehnart, S. E., Maier, L. S., and Hasenfuss, G. (2009). Abnormalities of calcium  
1241 metabolism and myocardial contractility depression in the failing heart. *Heart*  
1242 *Fail. Rev.* 14, 213–224. doi: 10.1007/s10741-009-9146-x  
1243 Li, Y. C., Pirro, A. E., Amling, M., Delling, G., Baron, R., Bronson, R., et al.  
1244 (1997). Targeted ablation of the vitamin D receptor: an animal model of vitamin  
1245 D-dependent rickets type II with alopecia. *Proc. Natl. Acad. Sci. U.S.A.* 94,  
1246 9831–9835. doi: 10.1073/pnas.94.18.9831  
1247 Liu, L. C., Voors, A. A., van Veldhuisen, D. J., van der Veer, E., Belonje, A. M.,  
1248 Szymanski, M. K., et al. (2011). Vitamin D status and outcomes in heart failure  
1249 patients. *Eur. J. Heart Fail.* 13, 619–625. doi: 10.1093/eurjhf/hfr032  
1250 Ma, Y., Yu, W. D., Kong, R. X., Trump, D. L., and Johnson, C. S.  
1251 (2006). Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt  
1252 and mitogen-activated protein kinase/extracellular signal-regulated kinase  
1253 kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D<sub>3</sub>-mediated  
1254 apoptosis in squamous cell carcinoma cells. *Cancer Res.* 66, 8131–8138. doi:  
1255 10.1158/0008-5472.CAN-06-1333  
1256 McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, P. M.,  
1257 et al. (2003). Phosphoinositide 3-kinase(p110α) plays a critical role for the  
1258 induction of physiological, but not pathological, cardiac hypertrophy. *Proc.*  
1259 *Natl. Acad. Sci. U.S.A.* 100, 12355–12360. doi: 10.1073/pnas.1934654100  
1260 Menegaz, D., Mizwicki, M. T., Barrientos-Duran, A., Chen, N., Henry, H. L., and  
1261 Norman, A. W. (2011). Vitamin D receptor (VDR) regulation of voltage-gated  
1262

1255 chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP).  
 1256 *Mol. Endocrinol.* 25, 1289–1300. doi: 10.1210/me.2010-0442

1257 Mizwicki, M. T., Keidel, D., Bula, C. M., Bishop, J. E., Zanello, L. P., Wurtz,  
 1258 J. M., et al. (2004). Identification of an alternative ligand-binding pocket in the  
 1259 nuclear vitamin D receptor and its functional importance in 1 $\alpha$ ,25(OH)<sub>2</sub>-  
 1260 vitamin D<sub>3</sub> signaling. *Proc. Natl. Acad. Sci. U.S.A.* 101, 12876–12881. doi: 10.  
 1261 1073/pnas.0403606101

1262 Mizwicki, M. T., and Norman, A. W. (2009). The vitamin D sterol-vitamin  
 1263 D receptor ensemble model offers unique insights into both genomic and  
 1264 rapid-response signaling. *Sci. Signal.* 2:re4. doi: 10.1126/scisignal.275re4

1265 Nass, R. D., Aiba, T., Tomaselli, G. F., and Akar, F. G. (2008). Mechanisms  
 1266 of disease: ion channel remodeling in the failing ventricle. *Nat. Clin. Pract.*  
 1267 *Cardiovasc. Med.* 5, 196–207. doi: 10.1038/ncpcardio1130

1268 Nattel, S., Maguy, A., Le Bouter, S., and Yeh, Y. H. (2007). Arrhythmogenic ion-  
 1269 channel remodeling in the heart: heart failure, myocardial infarction, and atrial  
 1270 fibrillation. *Physiol. Rev.* 87, 425–456. doi: 10.1152/physrev.00014.2006

1271 Norman, A. W., Henry, H. L., Bishop, J. E., Song, X. D., Bula, C., and Okamura,  
 1272 W. H. (2001a). Different shapes of the steroid hormone 1 $\alpha$ ,25(OH)<sub>2</sub>-  
 1273 vitamin D<sub>3</sub> act as agonists for two different receptors in the vitamin  
 1274 D endocrine system to mediate genomic and rapid responses. *Steroids* 66,  
 1275 147–158.

1276 Norman, A. W., Ishizuka, S., and Okamura, W. H. (2001b). Ligands for the vitamin  
 1277 D endocrine system: different shapes function as agonists and antagonists for  
 1278 genomic and rapid response receptors or as a ligand for the plasma vitamin D  
 1279 binding protein. *J. Steroid Biochem. Mol. Biol.* 76, 49–59. doi: 10.1016/S0960-  
 1280 0760(00)00145-X

1281 Norman, P. E., and Powell, J. T. (2014). Vitamin D and cardiovascular disease. *Circ.*  
 1282 *es.* 114, 379–393. doi: 10.1161/CIRCRESAHA.113.301241

1283 S, J., Chanet, A., Giraudet, C., Patrac, V., Pierre, P., Jourdan, M., et al. (2013).  
 1284 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> enhances the stimulating effect of leucine and insulin  
 1285 on protein synthesis rate through Akt/PKB and mTOR mediated pathways  
 1286 in murine C2C12 skeletal myotubes. *Mol. Nutr. Food Res.* 57, 2137–2146.  
 1287 doi: 10.1002/mnfr.201300074

1288 Sequeira, V. B., Rybchyn, M. S., Tongkao-On, W., Gordon-Thomson, C., Malloy,  
 1289 P. J., Nemere, I., et al. (2012). The role of the vitamin D receptor and ERp57 in  
 1290 photoprotection by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. *Mol. Endocrinol.* 26, 574–582.  
 1291 doi: 10.1210/me.2011-1161

1292 Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., et al.  
 1293 (2002). Akt/protein kinase B promotes organ growth in transgenic mice. *Mol.*  
 1294 *Cell. Biol.* 22, 2799–2809. doi: 10.1128/MCB.22.8.2799-2809.2002

1295 Takeuchi, S., Takagishi, Y., Yasui, K., Murata, Y., Toyama, J., and Kodama, I. (2000).  
 1296 Voltage-gated K(+)Channel, Kv4.2, localizes predominantly to the transverse-  
 1297 axial tubular system of the rat myocyte. *J. Mol. Cell. Cardiol.* 32, 1361–1369.  
 1298 doi: 10.1006/jmcc.2000.1172

1299 Tamayo, M., Manzanares, E., Bas, M., Martin-Nunes, L., Val-Blasco, A., Larriba,  
 1300 M. J., et al. (2017). Calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>) increases L-type  
 1301 calcium current via protein kinase A signaling and modulates calcium cycling  
 1302 and contractility in isolated mouse ventricular myocytes. *Heart Rhythm* 14,  
 1303 432–439. doi: 10.1016/j.hrthm.2016.12.013

1304 Tishkoff, D. X., Nibbelink, K. A., Holmberg, K. H., Dandu, L., and Simpson,  
 1305 R. U. (2008). Functional vitamin D receptor (VDR) in the t-tubules of cardiac  
 1306 myocytes: VDR knockout cardiomyocyte contractility. *Endocrinology* 149,  
 1307 558–564. doi: 10.1210/en.2007-0805

1308 Trépanier-Boulay, V., St-Michel, C., Tremblay, A., and Fiset, C. (2001). Gender-  
 1309 based differences in cardiac repolarization in mouse ventricle. *Circ. Res.* 89,  
 1310 437–444. doi: 10.1161/hh1701.095644

1311 Vertino, A. M., Bula, C. M., Chen, J. R., Almeida, M., Han, L., Bellido, T.,  
 1312 et al. (2005). Nongenotropic, anti-apoptotic signaling of 1 $\alpha$ ,25(OH)<sub>2</sub>-  
 1313 vitamin D<sub>3</sub> and analogs through the ligand binding domain of the vitamin D  
 1314 receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol  
 1315 3-, and JNK kinases. *J. Biol. Chem.* 280, 14130–14137. doi: 10.1074/jbc.M4107  
 1316 20200

1317 Weeks, K. L., Gao, X., Du, X. J., Boey, E. J., Matsumoto, A., Bernardo, B. C.,  
 1318 et al. (2012). Phosphoinositide 3-kinase p110 $\alpha$  is a master regulator of exercise-  
 1319 induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction.  
 1320 *Circ. Heart Fail.* 5, 523–534. doi: 10.1161/CIRCHEARTFAILURE.112.966622

1321 Witte, K. K., Byrom, R., Gierula, J., Paton, M. F., Jamil, H. A., Lowry, J. E., et al.  
 1322 (2016). Effects of Vitamin D on cardiac function in patients with chronic HF:  
 1323 the vindicate Study. *J. Am. Coll. Cardiol.* 67, 2593–2603. doi: 10.1016/j.jacc.  
 1324 2016.03.508

1325 Yang, K. C., Jay, P. Y., McMullen, J. R., and Nerbonne, J. M. (2012). Enhanced  
 1326 cardiac PI3K $\alpha$  signalling mitigates arrhythmogenic electrical remodelling in  
 1327 pathological hypertrophy and heart failure. *Cardiovasc. Res.* 93, 252–262.  
 1328 doi: 10.1093/cvr/cvr283

1329 Zanatta, L., Goulart, P. B., Gonçalves, R., Pierozan, P., Winkelmann-Duarte,  
 1330 E. C., Woehl, V. M., et al. (2012). 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> mechanism  
 1331 of action: modulation of L-type calcium channels leading to calcium uptake  
 1332 and intermediate filament phosphorylation in cerebral cortex of young  
 1333 rats. *Biochim. Biophys. Acta* 1823, 1708–1719. doi: 10.1016/j.bbamcr.2012.  
 1334 06.023

1335 Zanello, L. P., and Norman, A. (2006). 1 $\alpha$ ,25(OH)<sub>2</sub> vitamin D<sub>3</sub> actions on  
 1336 ion channels in osteoblasts. *Steroids* 71, 291–297. doi: 10.1016/j.steroids.2005.  
 1337 09.012

1338 Zhang, L., Yan, X., Zhang, Y. L., Bai, J., Hidru, T. H., Wang, Q. S., et al.  
 1339 (2018). Vitamin D attenuates pressure overload-induced cardiac remodeling  
 1340 and dysfunction in mice. *J. Steroid Biochem. Mol. Biol.* 178, 293–302.  
 1341 doi: 10.1016/j.jsbmb.2018.01.009

1342 Zhang, X., and Zanello, L. P. (2008). Vitamin D receptor-dependent 1  
 1343  $\alpha$ ,25(OH)<sub>2</sub> vitamin D<sub>3</sub>-induced anti-apoptotic PI3K/AKT signaling in  
 1344 osteoblasts. *J. Bone Miner. Res.* 23, 1238–1248. doi: 10.1359/jbmr.080326

1345 Zhang, Y., Zhang, J., and Studzinski, G. P. (2006). AKT pathway is activated by  
 1346 1, 25-dihydroxyvitamin D<sub>3</sub> and participates in its anti-apoptotic effect and cell  
 1347 cycle control in differentiating HL60 cells. *Cell Cycle* 5, 447–451. doi: 10.4161/  
 1348 cc.5.4.2467

**Conflict of Interest Statement:** The authors declare that the research was  
 1349 conducted in the absence of any commercial or financial relationships that could  
 1350 be construed as a potential conflict of interest.

*Copyright © 2018 Tamayo, Martin-Nunes, Val-Blasco, Piedras, Larriba, Gómez-  
 1351 Hurtado, Fernández-Velasco and Delgado. This is an open-access article distributed  
 1352 under the terms of the Creative Commons Attribution License (CC BY). The use,  
 1353 distribution or reproduction in other forums is permitted, provided the original  
 1354 author(s) and the copyright owner(s) are credited and that the original publication  
 1355 in this journal is cited, in accordance with accepted academic practice. No use,  
 1356 distribution or reproduction is permitted which does not comply with these terms.*